Vapers Digest 3rd July

Friday’s News at a glance:
THR.net Calls For Evidenced Policies ~ The ‘Donald Trump Of Fake Science’ ~ Prevalence and correlates of e-cigarette use among older adults aged 60 years and over ~ New CoEHAR study highlights the need for better Tobacco Harm Reduction strategies for older smokers ~ CAPHRA: Health policy fails when lived experience is ignored ~ Kenya’s Tobacco Control Bill Should Follow Science, Not Fear ~ The Spreadsheet at a Knife Fight ~ Rattled! ~ Who Gets to Be a Witness? ~ “The choice is often not between vaping and no vaping, but between a regulated market and an unregulated one”: an interview with Robert Beaglehole ~ Switching from a failed vape and tobacco policy to a successful one ~ MEP survey shows progress, confusion and a growing challenge for the Commission ~ After US FDA says ZYN pouches are less harmful, will Europe follow? ~ On Nicotine, FDA Embraces Science and Delivers a Public Health Victory ~ Australia’s $7 Billion Illicit and Contaminated Nicotine Market That Experts had Tirelessly Warned About ~ Nearly half of online pouch customers tried them to quit smoking or vaping, survey finds ~ Ireland moves closer to banning fruit and sweet vape flavours ~ Vaping linked to faster smoking decline in New Zealand, says Lancet paper ~ Why Consumer Voices Matter: The Missing Evidence in Public Debate ~ In Massachusetts, The ‘Nicotine-Free Generation’ Meets an Old Problem: Prohibition ~ Southern California’s total tobacco bans aren’t helping public health ~ Jessica Yingst, Let’s talk e-cigarettes, June 2026 ~ What The FDA’s Latest Ruling Could Mean For Future Of Nicotine Pouches
Two From Dave Cross, Planet Of The Vapes
THR.net Calls For Evidenced Policies
Tobacco Harm Reduction.net (THR.net) tells Planet of the Vapes that it has submitted formal evidence to the European Commission’s call for evidence on the revision of the Tobacco Products Directive and the Tobacco Advertising Directive. It says that it is urging policymakers to adopt a risk-proportionate framework that “reflects the scientific consensus and maximises the opportunity to reduce smoking-related deaths across Europe”.
The ‘Donald Trump Of Fake Science’
Europe’s Health Commissioner Oliver Várhelyi has come under fresh attack for the “Trumpification of EU health policy” following further misleading claims about nicotine, vaping and tobacco harm reduction. Várhelyi’s new statement, made on World No Tobacco Day, “relied on unsupported assertions, ignored the role of safer nicotine products in reducing smoking and used confusing statistics that blurred the distinction between youth and adult consumers”.
Prevalence and correlates of e-cigarette use among older adults aged 60 years and over
Yusuff Adebayo Adebisi, Anas Ali Alhur, Isaac Olushola Ogunkola, Najim Z Alshahrani, Don Eliseo Lucero-Prisno 3rd 6, Usman A Adeniran, Giulio Geraci, Venera Tomaselli, Riccardo Polosa, National Library of Medicine
Abstract
Purpose: E-cigarette use has increased substantially in the general population, yet evidence on use among older adults remains limited. Older adults bear a disproportionate burden of smoking-related morbidity and, in some populations, have shown persistently high smoking prevalence relative to younger age groups. Understanding the prevalence and correlates of e-cigarette use in this population is essential to inform targeted tobacco control and harm reduction strategies.
New CoEHAR study highlights the need for better
Tobacco Harm Reduction strategies for older smokers
Center of Excellence for the Acceleration of HArm Reduction (CoEHAR)
A new study by CoEHAR published in European Geriatric Medicine, highlights an often-overlooked population in tobacco control: older adults who smoke. Drawing on nationally representative data from the Scottish Health Survey (2017–2024), researchers analysed 13,297 adults aged 60 years and older to investigate the prevalence and characteristics of e-cigarette use in later life.
CAPHRA: Health policy fails when lived experience is ignored
Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA)
The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) says governments are still making avoidable health policy mistakes because they treat lived experience as optional.
In a new paper, The Value of Lived Experience in Health Policy Development, CAPHRA argues that people living with the real-world consequences of policy provide practical insight that can reduce delivery risk, strengthen trust, and prevent costly failure.
Joseph Magero, World Vapers’ Alliance
As Parliament considers the proposed Tobacco Control Amendment Bill, Kenya faces an important choice. Should nicotine products be regulated based on scientific evidence, or should all products continue to be treated as equally harmful regardless of their level of risk?
The recent decision by the U.S. Food and Drug Administration (FDA) offers an important lesson. After a rigorous scientific review, the FDA authorized reduced-risk marketing claims for certain nicotine pouches, concluding that adult smokers who switch completely from cigarettes can significantly reduce their risk of developing smoking-related diseases.
The Spreadsheet at a Knife Fight
Alan Gor
There is an old saying that you should never bring a knife to a gunfight, but in tobacco harm reduction some of the world’s most respected scientists made a more subtle and more consequential mistake: they brought spreadsheets to a knife fight they did not realise was happening.
For more than two decades, researchers studying reduced-risk nicotine products did exactly what modern academia trained them to do, designing randomised controlled trials, running toxicology assays, measuring biomarkers, mapping exposure pathways, reviewing epidemiological evidence, and publishing meticulous papers in peer-reviewed journals, refining uncertainty instead of slogans and assuming that if the evidence became strong enough and the methodology careful enough then public health institutions would eventually adjust course.
Rattled!
Christopher Snowdon, The Snowdon Substack
The EU’s plan to force member states to levy punitive taxes on e-cigarette fluid and nicotine pouches has not gone down well with the public. A consultation launched last year received 18,480 responses. The vast majority were opposed to the proposal.
This led to a frenzy of activity from a network of NGOs linked to Michael Bloomberg who spat their dummies out and called on the European Commission to disregard to the consultation. Aided and abetted by the useful idiots at Politico, they complained that it had been “swamped with pro-industry feedback”. The executive director of Action on Smoking and Health (USA) claimed that: “This isn’t democratic input,” he says, “it’s manufactured opposition.”
Who Gets to Be a Witness?
James Deighan
One of the strangest things about living through a moral panic is watching reality quietly move in the opposite direction.
A few days ago, the FDA published a graph that made me angrier than it probably should have.
Youth vaping is down.
Youth smoking is down.
Youth tobacco use is down.
Those are all good things.
So why was I irritated?
“The choice is often not between vaping and no vaping,
but between a regulated market and an unregulated one”: an interview with Robert Beaglehole
Jean-François Etter, Nicotine, tobacco and smoking cessation
Q: For readers who may not know you, could you tell us a little about yourself, what work you have done in the past in the field of tobacco control, and what you are currently doing in this area?
I trained in medicine in New Zealand and then in cardiology and public health in London and the USA. I come from a family that was severely affected by tobacco and have spent five decades working in chronic (non-communicable) disease epidemiology and tobacco control, much of it based at the University of Auckland in New Zealand. My last formal position was as Director of the Department of Chronic Diseases and Health Promotion at WHO, Geneva. In 1982 I started ASH (Action on Smoking and Health) NZ and am currently Chair of the ASH Board.
Switching from a failed vape and tobacco policy to a successful one
Ross Fitzgerald, Pearls And Irritations
Vaping nicotine was developed in 2003 by a Chinese chemist Hon Lik – a heavy smoker who was desperate to find an effective way to quit smoking after his father died from lung cancer.
Vaping was marketed in 2007 and within a few years it became increasingly popular, especially in America and the United Kingdom.
In Australia, the availability of vapes has been severely restricted, first in 2013 by requiring a doctor’s prescription, and then from October 2024, requiring legal vapes to be purchased from pharmacies.
POUCHFORUM
A new Tamarind Intelligence survey, published on the World Nicotine Congress website, gives a timely insight into how Members of the European Parliament view novel nicotine products. The survey shows a Parliament that is better informed than before, but also more divided. That division matters, because the next revision of EU tobacco and nicotine legislation will have to deal with a political reality that no longer fits the old tobacco control script.
After US FDA says ZYN pouches are less harmful, will Europe follow?
SnusForumet
The US Food and Drug Administration (FDA) has authorised ZYN brand nicotine pouches to be marketed as less harmful compared to cigarettes. Meanwhile, EU regulators continue to debate whether pouches should be banned altogether.
The FDA has approved 20 varieties of ZYN brand nicotine pouches to be marketed with a Modified Risk Tobacco Product (MRTP) claim.
The ruling allows the manufacturer, PMI, to inform adult consumers that completely switching from cigarettes to ZYN entails a lower risk of several serious diseases.
On Nicotine, FDA Embraces Science and Delivers a Public Health Victory
Martin Cullip, Real Clear Science
The Food and Drug Administration’s (FDA’s) latest decision on nicotine pouches marks one of the most important advances in American tobacco policy in years. By authorizing ZYN nicotine pouches to be marketed with a Modified Risk Tobacco Product (MRTP) claim, the FDA has done something that should have been at the heart of public health all along. It has allowed science, rather than ideology, to guide policy.
Following what the agency described as an “extensive scientific review,” the FDA authorized 20 ZYN products, concluding that they can be marketed with the claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
Australia’s $7 Billion Illicit and Contaminated Nicotine Market That Experts had Tirelessly Warned About
Diane Caruana, Vaping Post
For years, tobacco harm reduction advocates, economists, criminologists and some public health experts warned that Australia’s increasingly restrictive approach to vaping would produce predictable consequences. Policymakers were told that banning or severely restricting access to regulated nicotine products would not eliminate demand. Instead, it would push consumers toward unregulated markets, empower criminal networks and expose users to products with unknown ingredients. Today, those warnings are no longer theoretical.
Three From Clearing The Air
Nearly half of online pouch customers tried them to quit smoking or vaping, survey finds
Tim Hong
Nearly half of US online nicotine pouch customers first tried the products to quit smoking, vaping or both, according to a new survey that adds to the debate over how smoke-free nicotine alternatives should be regulated.
The report, released by Nicokick.com and Northerner.com, found that 46 per cent of surveyed customers cited quitting smoking, vaping or both as one reason they first used nicotine pouches.
It comes as UK campaigners warn that weak enforcement could leave the pouch market exposed to the same kind of illicit trade already seen in vapes.
Ireland moves closer to banning fruit and sweet vape flavours
Tim Hong
Ireland has moved closer to banning most flavoured vapes after new nicotine laws cleared the Dáil.
The Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 passed its final stage in the Dáil on Wednesday and will now go to the Seanad, where it is expected to be debated in July.
If enacted, the bill would sharply restrict the Irish vape market by limiting legal vape flavours to tobacco and unflavoured products. It would also clamp down on colourful packaging, point-of-sale displays and retail advertising.
Vaping linked to faster smoking decline in New Zealand, says Lancet paper
Ali Anderson
New Zealand’s adult smoking rate began falling much faster after 2018/19, as vaping became more widely available and was recognised as a quit aid.
The annual rate of decline in daily smoking became around five times faster among both all adults and Māori adults.
Daily adult smoking has now plateaued below seven per cent, with remaining smoking increasingly concentrated among Māori, older adults and more deprived communities.
Youth smoking remains very low, while youth vaping has fallen since tighter regulation was introduced.
Why Consumer Voices Matter: The Missing Evidence in Public Debate
Kurt Yeo, THR Global
Public debate has never been so accessible. The internet and social media provide a platform for almost anyone to have a say in conversations that can influence public opinion and, ultimately, public policy. Yet despite this unprecedented ability to communicate, many of the people most directly affected by policy decisions remain remarkably absent from the conversations that determine their future.
Governments consult experts. Researchers publish studies. Journalists interpret new findings. Advocacy organisations campaign passionately for change.
In Massachusetts, The ‘Nicotine-Free Generation’ Meets an Old Problem: Prohibition
Randall Bloomquist, NH Journal
The science on fighting cigarette smoking is clear, public health experts say: Prohibition doesn’t work.
But the politics? That can be very different.
In Massachusetts, more than 20 communities have adopted an age-based version of prohibition known as “Nicotine-Free Generation” (NFG) policies. It’s a lifetime ban on the purchase of all nicotine products for people born after a specific date.
Southern California’s total tobacco bans aren’t helping public health
Guy Bentley, Reason
Let’s say a government agency pays for a study and is involved in the study’s design, data collection, analysis, writing, and interpretation. Would you find it plausible that the agency had zero influence on the study’s results?
Last year, the academic journal Tobacco Control published just such a study, investigating what happened when Beverly Hills and Manhattan Beach became the first U.S. cities to ban the sale of all tobacco products within their city limits.
Jessica Yingst, Let’s talk e-cigarettes, June 2026
The University of Oxford
Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research and interview Jessica Yingst, Penn State Center for Research on Tobacco and Health, USA.
Associate Professor Jamie Hartmann-Boyce and Associate Professor Nicola Lindson discuss the new evidence in e-cigarette research and interview Dr Jessica Yingst. Dr Jessica Yingst is a member of the Penn State Center for Research on Tobacco and Health and is the co-director of the Career Enhancement Core with the Penn State Tobacco Center of Regulatory Science otherwise known as a TCORS. Jessica Yingst is a public health researcher focused on understanding methods to reduce harms associated with tobacco use.
What The FDA’s Latest Ruling Could Mean For Future Of Nicotine Pouches
Ireland Owens, Daily Caller
The Food and Drug Administration’s recent decision to allow certain nicotine pouches to be marketed as posing fewer health risks than cigarettes could potentially lead to the U.S. becoming smoke-free one day, according to one analyst.
The FDA said Tuesday it will let 20 of Swedish Match USA, Inc.’s ZYN nicotine pouch products be marketed to U.S. consumers with the risk modification claim that “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis,” according to the agency’s news release.
On this day…2017!
A look back at how things have moved on or otherwise…
Media Misinformation
Midnight Musings
It is quite staggering the amount of media misinformation that can be found even through incidental reading these days. This should come as no surprise to smokers and vapers who are well used to the amount of clickbait spouting downright lies that has been fed to the mainstream MSM by the tax-sponging public health ‘charities’ and organisations to justify their continued funding.
Innumeracy and junk science (part 3)
Carl V. Phillips, Anti-THR Lies
Estimating the health effect of a quantitative standard for an exposure is a matter of estimating the relevant range of the dose-response curve, along with knowing how much people’s dosage would change. That is, you need estimates like, “N people use product X, which has 5 ppm NNN, which causes Y risk per person, versus the Z risk per person from 1 ppm, so multiply N by (Y-Z)….” With such numbers we could estimate the effect of an adjustment in the NNN concentration.
Visit Nicotine Science & Policy for more News from around the World









